Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

Owing to recent advances in early reperfusion strategies, pharmacological therapy,
standardized care, and the identification of vulnerable patient subsets, the prognosis of …

Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …

Background The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza
vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against …

Aim Mortality from acute myocardial infarction (AMI) has declined, increasing the pool of
survivors at risk of later development of heart failure (HF). However, coronary reperfusion …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Background Data on the occurrence times of multiple outcomes, reflecting the temporal
profile of disease burden/progression, have been used to estimate treatment effects in …

In this review, we discuss what is meant by “foundational” therapy for patients with heart
failure and reduced ejection fraction (HFrEF) and the evidence supporting the use of the five …

Aim The win ratio can incorporate different types of outcomes and enhance statistical power,
making it a useful method for analysing composite outcomes in cardiovascular trials. The …

Background: In patients who survive an acute myocardial infarction (AMI), angiotensin-
converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events …